Loading clinical trials...
Loading clinical trials...
A Trial Comparing the Efficacy and Safety of Adding Liraglutide Versus Addition of Insulin Aspart With the Largest Meal to Insulin Degludec, Both in Combination With Metformin, in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification (BEGIN™: VICTOZA® ADD-ON)
Conditions
Interventions
insulin degludec
insulin aspart
+1 more
Locations
124
United States
Novo Nordisk Investigational Site
Concord, California, United States
Novo Nordisk Investigational Site
La Jolla, California, United States
Novo Nordisk Investigational Site
Lancaster, California, United States
Novo Nordisk Investigational Site
Los Angeles, California, United States
Novo Nordisk Investigational Site
National City, California, United States
Novo Nordisk Investigational Site
Northridge, California, United States
Start Date
September 1, 2011
Primary Completion Date
July 1, 2012
Completion Date
July 1, 2012
Last Updated
March 6, 2017
NCT06513026
NCT06815081
NCT06807190
NCT07517406
NCT07286747
NCT06278207
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions